Ibrutinib is not an effective drug in primografts of TCF3-PBX1.

ABSTRACT:

Aim

The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) express BTK and are sensitive to ibrutinib in vitro. However, preclinical studies in mice are lacking that justify clinical implementation.

Methods

Immunocompromised NSG mice were engrafted with a luciferase-positive TCF3-PBX1 leukemic cell line or primary leukemic cells and treated with ibrutinib or placebo. Additionally, primary cells were exposed in vitro to 4 main induction drugs as monotherapy and in combination with ibrutinib.

Results

Treatment with ibrutinib

SUBMITTER: van de Ven C 

PROVIDER: S-EPMC7306596 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature